| |
| . |
 24  1/2  |
|
|
|
Subject |
Hyundai Pharm, Type 2 Diabetes Drug Novel Candidate Selected for 2nd Step Development by Government Support |
Content |
- Ministry of Commerce, Industry and Energy Selects Excellence Technology Center (ATC) business 'continued challenges'
- Hyundai Pharm. For Next 3 Years, Plans to Invest 2.7 Million USD including Government Funding
Hyundai Pharm (President Yeong Hak Kim) was selected for the Type 2 Diabetes treatment development targeting GPR 119 receptor by ATC (Advanced Technology Center of Excellence) business sponsored by Ministry of Commerce, Industry and Energy.
GPR119 receptors are located in chapters and pancreas and promote secretion of GLP-1 which lowers glucose and effects in suppressing in weight gain. HD0472936, GPR 119 receptor agonist the novel drug molecule, is expected to lower blood glucose and weight gain reduction effect and showed an excellent efficacy in lowering blood glucose and reducing weight in animal study.
After selected as ATC new project in 2012, GPR119 receptor agonist substance is once again received spotlight from the government for its research value; Hyundai Pharm plans to invest 2.7 Million USD including government funding conducting non-clinical and clinical studies to develop novel drug candidate to become a global novel drug.
Yeong Hak Kim, the President of Hyundai Pharm, said, “By selecting as ATC business “Continued Challenges”, GPR 119 receptor agonist molecule once again is recognized for its growth potential as a new Type 2 Diabetes treatment.”
Hyundai Pharm is investing more than 8% of its annual sales in order to become a pharmaceutical company specialized in Type 2 Diabetes treatment and engaging an active discussion with experts from domestic and over-seas to expand items in novel research development. |
Date |
2014-06-30 |
|
 |
 |
 |
|
